Literature DB >> 23223594

Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts.

Giota Touloumi1, Nikos Pantazis, Deenan Pillay, Dimitrios Paraskevis, Marie-Laure Chaix, Heiner C Bucher, Claudia Kücherer, Robert Zangerle, Anne-Marte Bakken Kran, Kholoud Porter.   

Abstract

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) subtype may influence disease progression. We compared CD4 lymphocyte cell count levels at seroconversion, decline rates and viral load set point in individuals infected with different HIV-1 subtypes.
METHODS: We used data from the Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE) collaboration, restricted to those infected since 1996, aged ≥15 years, and applied mixed effects models for CD4 cell count decline and median regression for viral load set point (mean level 6-24 months from seroconversion).
RESULTS: The analysis included 3364 seroconverters with known HIV-1 subtypes. Compared with subtype B, CD4 at seroconversion was significantly higher for subtype CRF01 and lower for subtype C. Subsequent CD4 decline was significantly slower for subtypes A and CRF02 and marginally slower for subtype C compared with B. Mean CD4 loss at 2 years of seroconversion for white men exposed through sex between men, aged 30-39 years, having seroconverted since 2006, enrolled within 6 months of seroconversion, and without acute infection was 88, 142, 100, 130, 103, and 167 cells/µL for subtypes A, B, C, CRF01_AE, CRF02_AG, and G, respectively. In adjusted analysis, median viral load set point and time to clinical AIDS/death did not differ significantly by subtype, although all subtypes, except C, tended to have lower levels compared with B.
CONCLUSIONS: HIV-1 subtype significantly influences seroconversion CD4 cell levels and decline rates but not viral load set point. These findings may be helpful to HIV-positive individuals and their attending physicians in understanding disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23223594     DOI: 10.1093/cid/cis1000

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  39 in total

1.  Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men.

Authors:  Martin Hoenigl; Nadir Weibel; Sanjay R Mehta; Christy M Anderson; Jeffrey Jenks; Nella Green; Sara Gianella; Davey M Smith; Susan J Little
Journal:  Clin Infect Dis       Date:  2015-04-22       Impact factor: 9.079

2.  Estimates of the Time From Seroconversion to Antiretroviral Therapy Initiation Among People Newly Diagnosed With Human Immunodeficiency Virus From 2006 to 2015, New York City.

Authors:  McKaylee M Robertson; Sarah L Braunstein; Donald R Hoover; Sheng Li; Denis Nash
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

3.  Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments.

Authors:  Trevor A Crowell; Donn J Colby; Suteeraporn Pinyakorn; James L K Fletcher; Eugène Kroon; Alexandra Schuetz; Shelly J Krebs; Bonnie M Slike; Louise Leyre; Nicolas Chomont; Linda L Jagodzinski; Irini Sereti; Netanya S Utay; Robin Dewar; Rungsun Rerknimitr; Nitiya Chomchey; Rapee Trichavaroj; Victor G Valcour; Serena Spudich; Nelson L Michael; Merlin L Robb; Nittaya Phanuphak; Jintanat Ananworanich
Journal:  Clin Infect Dis       Date:  2018-05-02       Impact factor: 9.079

4.  Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection.

Authors:  Martin Hoenigl; Dominique L Braun; Roger Kouyos; Huldrych F Günthard; Susan J Little
Journal:  J Acquir Immune Defic Syndr       Date:  2017-04-01       Impact factor: 3.731

5.  Rapid disease progression in HIV-1 subtype C-infected South African women.

Authors:  Koleka Mlisana; Lise Werner; Nigel J Garrett; Lyle R McKinnon; Francois van Loggerenberg; Jo-Ann S Passmore; Clive M Gray; Lynn Morris; Carolyn Williamson; Salim S Abdool Karim
Journal:  Clin Infect Dis       Date:  2014-07-17       Impact factor: 9.079

6.  HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.

Authors:  Anjali Joshi; Emily K Cox; Melina J Sedano; Erin B Punke; Raphael Tc Lee; Sebastian Maurer-Stroh; Palvinder Kaur; Oon Tek Ng; Himanshu Garg
Journal:  Virology       Date:  2017-10-09       Impact factor: 3.616

7.  The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

Authors:  Marina B Klein; Jim Young; David Dunn; Bruno Ledergerber; Caroline Sabin; Alessandro Cozzi-Lepri; Francois Dabis; Richard Harrigan; Darrell H Tan; Sharon Walmsley; John Gill; Curtis Cooper; Alexandra U Scherrer; Amanda Mocroft; Robert S Hogg; Fiona Smaill
Journal:  CMAJ Open       Date:  2014-10-01

8.  When to start antiretroviral therapy: the need for an evidence base during early HIV infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred M Gordin; Álvaro H Borges; James D Neaton
Journal:  BMC Med       Date:  2013-06-14       Impact factor: 8.775

9.  Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation.

Authors:  Trevor A Crowell; Justin Ritz; Robert W Coombs; Lu Zheng; Joseph J Eron; John W Mellors; Joan Dragavon; Gert U van Zyl; Javier R Lama; Kiat Ruxrungtham; Beatriz Grinsztejn; Roberto C Arduino; Lawrence Fox; Jintanat Ananworanich; Eric S Daar
Journal:  Clin Infect Dis       Date:  2021-08-02       Impact factor: 20.999

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.